NCT02489318 2026-04-13
TITAN
Aragon Pharmaceuticals, Inc.
Phase 3 Active not recruiting
Clinical Trials
14 trialsNCT03767244 2026-04-13
PROTEUS
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT04108208 2026-04-13
A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)
Janssen Research & Development, LLC
Phase 4 Active not recruiting
NCT06952803 2026-03-10
EvoPAR-PR02
AstraZeneca
Phase 3 Recruiting
NCT04736199 2026-02-27
ARANOTE
Bayer
Phase 3 Completed
NCT04034095 2025-12-15
A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan
Janssen Pharmaceutical K.K.
Completed
NCT03523338 2025-12-10
An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant Prostate Cancer
Aragon Pharmaceuticals, Inc.
No longer available
NCT05171387 2025-06-22
Darolutamide + Androgen Deprivation Therapy (ADT) in Chinese Men With High Risk, Nonmetastatic Prostate Cancer
Bayer
Phase 2 Completed
NCT06765954 2025-05-06
Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.
ImmunityBio, Inc.
Phase 2 Not yet recruiting
NCT05067140 2025-03-17
A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer
Novartis
Phase 1/2 Active not recruiting
NCT01715285 2025-02-04
A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)
Janssen Research & Development, LLC
Phase 3 Completed
NCT02918968 2024-12-09
Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer
Astellas Pharma Inc
Phase 4 Completed
NCT02217566 2020-01-13
Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy
Janssen Research & Development, LLC
Phase 2 Completed
NCT00242567 2014-05-07
Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate Cancer
Novartis
Phase 3 Completed